Literature DB >> 16122479

Expression of bone morphogenetic proteins in human lung carcinomas.

Elaine M Langenfeld1, John Bojnowski, John Perone, John Langenfeld.   

Abstract

BACKGROUND: The bone morphogenetic proteins (BMP) are phytogenetically conserved proteins, which are essential for embryonic development. Bone morphogenetic protein-2 (BMP-2) was recently shown to be expressed in a small sample of lung carcinomas. Studies have suggested that BMP-2 may enhance tumor growth. The present study examined which BMP family members are expressed in non-small cell lung carcinomas (NSCLC). Furthermore, the frequency of BMP-2 overexpression and the types of lung carcinomas expressing BMP-2 were determined.
METHODS: Tissue samples were obtained from the operating room and frozen in liquid nitrogen. Samples included metastatic NSCLC, benign lung tumors, adenocarcinoma, squamous cell carcinoma, bronchioloalveolar, and neuroendocrine carcinomas. Paired normal lung tissues served as the controls. The BMP-2, BMP-4, BMP-6, BMP-7, and growth differentiation factor 5 (GDF-5) expressions were examined by Western blot analysis.
RESULTS: The BMP-4, BMP-6, BMP-7, and GDF-5 were infrequently expressed in NSCLC. The BMP-2 was expressed in 41 of 42 NSCLC with minimal expression in normal lung tissue; BMP-2 was expressed 17 fold higher than that of normal lung tissue. The BMP-2 was over-expressed in all subtypes of NSCLC, including neuroendocrine carcinomas. The BMP-2 expression was similar between squamous cell carcinomas and adenocarcinomas; however, bronchioloalveolar carcinomas tended to have a lower level of expression. The BMP-2 was not significantly expressed in benign lung tumors.
CONCLUSIONS: Bone morphogenetic protein-2 is the predominant family member expressed in NSCLC. The BMP-2 is overexpressed in the majority of human lung carcinomas independent of cell type.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16122479     DOI: 10.1016/j.athoracsur.2005.03.094

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  35 in total

1.  Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Authors:  Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2011-04-22       Impact factor: 4.944

2.  Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.

Authors:  Jenna H Newman; David J Augeri; Rachel NeMoyer; Jyoti Malhotra; Elaine Langenfeld; Charles B Chesson; Natalie S Dobias; Michael J Lee; Saeed Tarabichi; Sachin R Jhawar; Praveen K Bommareddy; Sh'Rae Marshall; Evita T Sadimin; John E Kerrigan; Michael Goedken; Christine Minerowicz; Salma K Jabbour; Shengguo Li; Mary O Carayannopolous; Andrew Zloza; John Langenfeld
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

Review 3.  The Yin and Yang of bone morphogenetic proteins in cancer.

Authors:  Ashok Singh; Rebecca J Morris
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-04       Impact factor: 7.638

4.  Bone morphogenetic protein-focused strategies to induce cytotoxicity in lung cancer cells.

Authors:  Anastasios Fotinos; Narayani Nagarajan; Adriano S Martins; David T Fritz; Diane Garsetti; Annette T Lee; Charles C Hong; Melissa B Rogers
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

5.  The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients.

Authors:  Xiangshan Yang; Daotang Li; Shaomei Cheng; Kaixi Fan; Lijun Sheng; Jing Zhang; Bin Feng; Zhongfa Xu
Journal:  Tumour Biol       Date:  2014-08-07

6.  Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers.

Authors:  Chandramohan Kattamuri; David M Luedeke; Kristof Nolan; Scott A Rankin; Kenneth D Greis; Aaron M Zorn; Thomas B Thompson
Journal:  J Mol Biol       Date:  2012-10-09       Impact factor: 5.469

7.  Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.

Authors:  Ying Ma; Lin Ma; Quan Guo; Shulan Zhang
Journal:  J Exp Clin Cancer Res       Date:  2010-06-30

8.  Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion.

Authors:  Chanèle Cyr-Depauw; Jason J Northey; Sébastien Tabariès; Matthew G Annis; Zhifeng Dong; Sean Cory; Michael Hallett; Jonathan P Rennhack; Eran R Andrechek; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

9.  Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes.

Authors:  Joon Won Yoon; Richard Gilbertson; Stephen Iannaccone; Philip Iannaccone; David Walterhouse
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

10.  Differential expression of cancer-related genes by single and permanent exposure to bone morphogenetic protein 2.

Authors:  Susanne Steinert; Torsten C Kroll; Isabel Taubert; Larissa Pusch; Peter Hortschansky; Klaus Höffken; Stefan Wölfl; Joachim H Clement
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-30       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.